Dr. Eric Horlick is an interventional cardiologist at the Peter Munk Cardiac Centre and an Assistant Professor of Medicine at University of Toronto. Since obtaining his medical degree from McGill University in Montreal, Quebec in 1996, Dr. Horlick has been the recipient of the Sanofi Cardiovascular Research Fellowship and the Julio Chavez Young Investigator Award from the International Congress of Cardiology among other honours. He has also co-authored many studies in respected publications, including American Heart Journal, Circulation, Journal of the American College of Cardiology, Heart and the International Journal of Cardiology, and has been invited to speak to physician audiences in the United States, Canada, Australia, Germany and Saudi Arabia. He is a member of the American College of Cardiology and a Fellow of the Society for Cardiovascular angiography and intervention.
Dr. Horlick started his career at University Health Network as a fellow studying percutaneous (through the skin) coronary intervention, and proceeded to do research in and training adult congenital interventional cardiology. Dr. Horlick’s expertise lies in performing surgical or minimally invasive procedures to treat structural heart disease. He is considered a key opinion leader in transcatheter valve therapies for the aortic and pulmonary valves. He works closely with the Division of Cardiovascular Surgery at the University Health Network. In a ground breaking surgical intervention in 2006, Dr. Horlick and a team of surgeons at Toronto General Hospital performed a new edge-to-edge percutaneous mitral valve repair on a patient with a leaking heart valve. The condition usually requires open-heart surgery, but with this new technique, patients recover faster and have reduced hospital stays. Dr. Horlick continues to work with the latest valve replacement technology to improve surgical outcomes and patients’ quality of life. Dr. Horlick recently provided physician training to all of Europe for a new Transcatheter Pulmonary Valve. He is actively involved in training physicians around the world in new structural and valvular heart disease therapies.
Industry Expertise (2)
Areas of Expertise (4)
Aortic Valve Disease
Media Appearances (2)
Inaugural Peter Munk Chair in Structural Heart Disease Intervention Announced
Building on a growing international reputation as one of the world’s leading centres with specialized expertise in the areas of congenital heart and cardiac valve disease, the Peter Munk Cardiac Centre today named Dr. Eric Horlick, cardiologist and Associate Professor of Medicine at the University of Toronto as the Chair of the inaugural Peter Munk Chair in Structural Heart Disease Intervention, which focuses on the management of inherited or acquired heart defects through a minimally invasive approach...
A team approach to mending broken hearts
Cusimano is working with cardiologists Dr. Eric Horlick and Dr. Mark Osten on this case. Cusimano is an expert at operating through tricky incisions; Horlick and Osten are experts at non-invasive techniques, such as TAVI.
“We take the skills of multiple people and use them on patients with complex problems,” Horlick says. “In the past, patients like this would get morphine and an apology.”
To assess the efficacy of clopidogrel, used in addition to taking aspirin, for the prevention of migraine attacks following ASD closure. Design, Setting, and Participants Randomized, double-blind clinical trial performed in 6 university hospitals in Canada.
Aortic valve disease in the setting of a left ventricular assist device presents unique challenges. We present the case of a patient who underwent transcatheter aortic valve implantation to replace a stenotic aortic valve to facilitate left ventricular assist device explantation. Thirty-three days later, the porcine pericardial valve cusps were fused and a thick pseudomembrane had occluded the left ventricular outflow tract, forcing the explant to be aborted.
This study sought to evaluate the long-term outcomes after transcatheter aortic valve implantation (TAVI) in the Multicenter Canadian Experience study, with special focus on the causes and predictors of late mortality and valve durability.
To examine the outcomes in patients with moderate or severe pulmonary arterial hypertension (PAH) undergoing percutaneous atrial septal defect (ASD) closure.
We set out to study the effect of transcatheter closure of atrial septal defect (ASD) on right ventricular (RV) and left ventricular (LV) function assessed by myocardial performance index (MPI), as well as left atrial (LA) volumes.